Harvard Bioscience, Inc. (HBIO) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $0.60, representing a downside of 89.5% from the current price $5.74.
Analysts estimate Earnings Per Share (EPS) of $0.45 and revenue of $0.09B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.28 vs est $0.45 (missed -162.2%). 2025: actual $-12.80 vs est $0.30 (missed -4366.7%). Analyst accuracy: 0%.
HBIO Stock — 12-Month Price Forecast
$0.60
▼ -89.55% Downside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Harvard Bioscience, Inc., the price target is $0.60.
The average price target represents a -89.55% change from the last price of $5.74.
HBIO Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Harvard Bioscience, Inc. in the past 3 months
EPS Estimates — HBIO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.28
vs Est $0.45
▼ 260.7% off
2025
Actual –$12.80
vs Est $0.30
▼ 102.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect the company to turn profitable.
Revenue Estimates — HBIO
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.094B
vs Est $0.094B
▲ 0.4% off
2025
Actual $0.087B
vs Est $0.086B
▲ 0.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
